OT (in part)
Rick,
<<This sort of release was THE sector standard, first 15 years or so for biotech. It's certainly the way that I'd do it, now or then.>>
After almost 10 years of the bio sector investing *games* I am very tired. I am tired like 80-years old man. Why! Why can not be simple and strait forward release where anyone with little efforts can come to informed conclusion? Why always need to be wrapped up in golden-paper? Why I need to dig deep, dig very deep, to pull out small fragments than can (or can not) help me to generate opinion?
In ALXN's Pexe case it was few notes and numbers on poster presentation (for last two-three years, PI/IIa and PIIb data) that point (to me) that they are actually gambling with PIII Primo trial.
The some story is ongoing, ongoing, and ongoing, for almost EVERY bios. Only reasons and excuses for withholding important data are changing from case to case. You can start with VPHM and Pleconaril, or any other bio. Always the some story.
Yes, we can make money, one way or another, but for next period (I see this at least next 5 years) it will be game where deep pocket will cash chips and small investors left with luck, if they have any.
Game is far from FAIR ! And bios are not helping at all. This is where they will not get any credit from me regardless what is outcome at the end.
Miljenko |
